Association of periconceptional folate supplements and FOLR1 and FOLR2 gene polymorphisms with risk of congenital heart disease in offspring: A hospital-based case-control study.
10.11817/j.issn.1672-7347.2022.200992
- Author:
Xinli SONG
1
;
Peng HUANG
2
;
Tingting WANG
3
;
Senmao ZHANG
3
;
Letao CHEN
3
;
Jiabi QIN
4
Author Information
1. Department of Epidemiology and Health Statistics, Xiangya School of Public Health, Central South University, Changsha 410078. 1461661756@qq.com.
2. Department of Cardiothoracic Surgery, Hunan Children's Hospital, Changsha 410007, China.
3. Department of Epidemiology and Health Statistics, Xiangya School of Public Health, Central South University, Changsha 410078.
4. Department of Epidemiology and Health Statistics, Xiangya School of Public Health, Central South University, Changsha 410078. qinjiabi123@163.com.
- Publication Type:Journal Article
- Keywords:
FOLR1 gene;
FOLR2 gene;
case-control study;
congenital heart disease;
interaction effects
- MeSH:
Case-Control Studies;
Dietary Supplements;
Female;
Folate Receptor 1/genetics*;
Folate Receptor 2/genetics*;
Folic Acid/administration & dosage*;
Heart Defects, Congenital/genetics*;
Hospitals;
Humans;
Infant;
Polymorphism, Single Nucleotide;
Prospective Studies;
Risk Factors
- From:
Journal of Central South University(Medical Sciences)
2022;47(1):52-62
- CountryChina
- Language:English
-
Abstract:
OBJECTIVES:Maternal periconceptional folic acid supplement is by far the most effective primary prevention strategy to reduce the incidence of congenital heart disease (CHD) in offspring. It was revealed that the underlying mechanisms are complex, including a combination of genetic and environmental factors. The purpose of this study is to investigate the association between periconceptional folic acid supplement, the genetic polymorphisms of maternal folic acid receptor 1 gene (FOLR1) and folic acid receptor 2 gene (FOLR2) and the impact of their interaction on the risk of CHD in offspring, and to provide epidemiological evidence for individualized folic acid dosing in hygienic counseling.
METHODS:A case-control study on 569 mothers of CHD infants and 652 mothers of health controls was performed. The interesting points were periconceptional folate supplements, single nucleotide polymorphisms (SNPs) of maternal FOLR1 gene and FOLR2 gene.
RESULTS:Mothers who took folate in the periconceptional period were observed a decreased risk of CHD [adjusted odds ratio (aOR)=0.58, 95% CI 0.35 to 0.95]. Our study also found that polymorphisms of maternal FOLR1 gene at rs2071010 (G/A vs G/G: aOR=0.67, 95% CI 0.47 to 0.96) and FOLR2 gene at rs514933 (T/C vs T/T: aOR=0.60, 95% CI 0.43 to 0.84; C/C vs T/T: aOR=0.55, 95% CI 0.33 to 0.90; the dominant model: T/C+ C/C vs T/T: aOR=0.59, 95% CI 0.43 to 0.81; and the addictive model: C/C vs T/C vs T/T: aOR=0.70, 95% CI 0.56 to 0.88) were significantly associated with lower risk of CHD [all P<0.05, false discovery rate P value (FDR_P)<0.1]. Besides, significant interaction between periconceptional folate supplements and rs2071010 G→A (aOR=0.59, 95% CI 0.41-0.86) and rs514933 T→C (aOR=0.52, 95% CI 0.37 to 0.74) on CHD risk were observed (all P<0.05, FDR_P<0.1).
CONCLUSIONS:Periconceptional folate supplements, polymorphisms of FOLR1 gene and FOLR2 gene and their interactions are significantly associated with risk of CHD. However, more studies in different ethnic populations with a larger sample and prospective designs are required to confirm our findings.
